International Journal of Rheumatic Diseases最新文献

{"title":"Neutralization of IL-17 and CXCR1 Protects Septic Arthritis by Regulating CXCL8-CXCR1 Pathway Along With Functional Activities in Neutrophils","authors":"Sharmistha Ghosh,&nbsp;Biswadev Bishayi","doi":"10.1111/1756-185X.70144","DOIUrl":"https://doi.org/10.1111/1756-185X.70144","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The main objective of this study is to elucidate the role of CXCR1 Ab, IL-17 Ab, and gentamicin in protecting septic arthritis by regulating neutrophil functional responses while evaluating the contribution of the CXCL8-CXCR1 pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eighty-four experimental swiss albino mice were utilized to study septic arthritis. They were divided into eight groups. After developing sepsis, respective mice groups were treated with CXCR1 Ab, IL-17 Ab, and gentamicin doses. Doses were administered on days 1, 8, and 13 of the experimental schedule. At the early, middle, and late phases of the experiment i.e. at 3, 10, and 15 DPI (Days Post Infection), mice were sacrificed and blood and tissues were collected for further experimental evaluations. Different functional studies were performed on isolated blood neutrophils, spleen, and synovial tissues. Histological evaluation, immunofluorescence study, sepsis profile, and downstream signaling pathway analysis were done to obtain data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Infected mice group exhibited high inflammatory responses while treatment helped to mitigate them. IL-17 neutralization helped to lower bacterial burden, neutrophil ROS activity, MPO activity, and ALP activity. However, the combined neutralization of CXCR1 and IL-17 greatly influenced PMN chemotactic activity and lysozyme activity. At the early phase of the experiment, IL-17 neutralization's impact was more prominent, while later, CXCR1 neutralization gained the upper hand.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We can conclude that IL-17 Ab in combination with gentamicin is potent in modulating neutrophil activities positively to cure sepsis, while CXCR1 Ab, through the CXCL8/CXCR1 pathway, regulates neutrophil functional activities by impacting different downstream signaling cascades.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticytokine (Ligand) Antibody Versus Antireceptor Antibody in Treating Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases","authors":"Hideto Kameda,&nbsp;Reina Maezawa,&nbsp;Yasuto Minegishi,&nbsp;Chihiro Imaizumi,&nbsp;Takehisa Ogura","doi":"10.1111/1756-185X.70202","DOIUrl":"https://doi.org/10.1111/1756-185X.70202","url":null,"abstract":"&lt;p&gt;Intracellular signaling through specific ligand-receptor interactions on the cellular membrane is essential for network communication among various immune cells in immune-mediated inflammatory diseases (IMIDs) [&lt;span&gt;1&lt;/span&gt;]. Therapeutic agents extracellularly inhibit this signaling through biological agents and intracellular inhibition via synthetic compounds such as kinase inhibitors (Figure 1). Although the differences between biological agents and kinase inhibitors, as well as among targeted cytokines, have been widely discussed, comparisons between anticytokines (ligands) and antireceptor antibodies remain limited.&lt;/p&gt;&lt;p&gt;Interleukin-6 (IL-6) inhibition is an example of a distinction between these antibodies. The discovery and cDNA cloning of IL-6 and its receptor, as well as the signaling molecule glycoprotein 130 (gp130), have been pivotal for the successful management of various IMIDs through the inhibition of IL-6 signaling [&lt;span&gt;2&lt;/span&gt;]. Tocilizumab, an anti-IL-6 receptor (IL-6R) antibody, was first developed in Japan and approved for the treatment of Castleman disease in 2005, followed by rheumatoid arthritis (RA) and juvenile idiopathic arthritis (both polyarticular and systemic) in 2008. Tocilizumab has been globally approved for various IMIDs, including giant cell arteritis and chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The subsequent development of biological agents targeting IL-6R, such as sarilumab, and those targeting IL-6 ligands, including sirukumab, clazakizumab, and olokizumab, has provided valuable insights into the difference between anticytokine and antireceptor antibodies [&lt;span&gt;3&lt;/span&gt;]. RA treatment with sarilumab has been successful in clinical trials [&lt;span&gt;4-8&lt;/span&gt;], with acceptable safety profiles identified through postmarketing surveillance [&lt;span&gt;9, 10&lt;/span&gt;]. However, the clinical development of biological agents targeting IL-6 ligands presents several challenges [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The most notable difference between anti-IL-6 and anti-IL-6R blockades lies in the efficiency of neutralizing the target functions within the selected dosing regimens. In our Japanese cohort, the median (interquartile range) serum IL-6 and IL-6R concentrations in treatment-naïve patients with RA were 4.70 (1.51–8.54) pg/mL and 84.2 (62.2–98.0) ng/mL, respectively [&lt;span&gt;11&lt;/span&gt;]. Similarly, an RA study in Poland reported median (range) serum IL-6 and IL-6R concentrations of 34.1 (1.5–234.0) pg/mL and 45.366 (17.288–81.760) ng/mL, respectively [&lt;span&gt;12&lt;/span&gt;]. Therefore, optimal dosing with limited dosing ranges is feasible for anti-IL-6R but not for anti-IL-6 ligands. For example, IL-6 receptor occupancy at steady-state trough levels was 98% or above with 200 mg of subcutaneous sarilumab every 2 weeks and 162 mg of tocilizumab weekly [&lt;span&gt;13&lt;/span&gt;]. Another example is the failure of treatment in people with RA with extremely high serum tumor necrosis factor ","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belimumab in Childhood Onset SLE: Update and Evidence","authors":"Tui Lin Yen,&nbsp;Su-Boon Yong,&nbsp;Chin-Yuan Yii,&nbsp;Chao-Yi Wu","doi":"10.1111/1756-185X.70207","DOIUrl":"https://doi.org/10.1111/1756-185X.70207","url":null,"abstract":"&lt;p&gt;Childhood onset systemic lupus erythema (cSLE) or pediatric onset SLE is a rare autoimmune disease among children and young adolescents, accounting for 10%–20% of all SLE patients. cSLE has a reported incidence rate of 0.3–0.9 per 100,000 children-years and a prevalence ranging from 3.3 to 8.8 per 100,000 children [&lt;span&gt;1&lt;/span&gt;]. The average age of presentation of cSLE is 11–12, and it rarely happens in children aged below 5 [&lt;span&gt;2&lt;/span&gt;]. Previous studies have concluded that cSLE is more common in females than males with a ratio of 4–5:1, but the sex ratio was lower compared to adult SLE, with a ratio of 9:1 [&lt;span&gt;1&lt;/span&gt;]. In contrast to adult SLE, cSLE patients usually have greater accrual of damage, higher disease activity, more frequent organ involvement, and worse outcomes compared to adult onset SLE [&lt;span&gt;3, 4&lt;/span&gt;]. Other studies have shown a higher risk of developing major depression in cSLE patients and juvenile SLE patients compared to adult onset SLE [&lt;span&gt;5&lt;/span&gt;], posing a great challenge for treatment and maintaining quality of life.&lt;/p&gt;&lt;p&gt;Before the recent breakthrough of biologic in SLE treatment, hydroxychloroquine, glucocorticoids, and immunosuppressants were the main treatment options for SLE [&lt;span&gt;6&lt;/span&gt;]. Despite standard regime's efficacy in disease control, it also compromised patient immunity, making infection one of the major causes of morbidity and mortality in the SLE population [&lt;span&gt;7&lt;/span&gt;]. Nonetheless, osteoporosis, cataracts, and coronary artery disease are significant side effects that should not be overlooked in long-term steroid users [ref]Above all these complications, children and adolescents before puberty are more likely to be exposed to prolonged high-dosed corticosteroid treatment and are more vulnerable. Long-term use of supraphysiological doses of corticosteroids, undernutrition, altered body composition with lean mass reduction, physical inactivity, delays in pubertal onset, or slow pubertal progression [&lt;span&gt;8&lt;/span&gt;]. The need for steroid-sparing agents to achieve better disease control is therefore urgent for this population.&lt;/p&gt;&lt;p&gt;Trial of belimumab in children with lupus was reported in 2020 by Brunner et al. [&lt;span&gt;9&lt;/span&gt;] suggesting that intravenous pharmacokinetics and benefit–risk profile in cSLE are consistent with adult belimumab studies.&lt;/p&gt;&lt;p&gt;To assess the efficacy and potential complications of belimumab in children, we aim to review the latest real-world evidence of its use in patients under the age of 18. We conducted a literature search on PubMed using keywords “Belimumab,” “SLE,” “systemic lupus erythematosus,” “lupus nephritis,” “lupus,” “childhood onset,” “childhood,” “pediatric,” “juvenile,” “children,” and filtered literature published in the last 5 years; the search term is as follows:&lt;/p&gt;&lt;p&gt;&lt;i&gt;(Belimumab[Title/Abstract]) AND ((((SLE[Title/Abstract]) OR (systemic lupus erythematosus[Title/Abstract])) OR (lupus nephritis[Title/Abstract])) OR (lupus[Title/Ab","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Risk of Frailty Progression Based on 5-Year Data in Patients With Rheumatoid Arthritis: A Multicenter Observational Study (T-FLAG)","authors":"Yoshifumi Ohashi,&nbsp;Mochihito Suzuki,&nbsp;Yasumori Sobue,&nbsp;Kenya Terabe,&nbsp;Shuji Asai,&nbsp;Shiro Imagama,&nbsp;Nobunori Takahashi","doi":"10.1111/1756-185X.70162","DOIUrl":"https://doi.org/10.1111/1756-185X.70162","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To examine risk factors for non-frailty rheumatoid arthritis (RA) patients progressing to frailty.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 304 RA patients with records for frailty assessment based on the Japanese Cardiovascular Health Study (J-CHS) criteria from 2020 to 2024 were included. Patients classified as non-frail (J-CHS scores 0–3) in 2020 were followed annually, and those who did and did not progress to frailty were categorized into the frailty progression (<i>n</i> = 100) and non-frailty progression (<i>n</i> = 204) groups, respectively. Risk factors for frailty progression were analyzed using the Cox proportional hazards model. Changes in DAS28-ESR and HAQ-DI between baseline and frailty progression were compared using a paired <i>t</i>-test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the non-frailty progression group, the frailty progression group was older (62.9 vs. 68.5 years) and had a longer duration of disease (9.1 vs. 14.2 years), lower methotrexate (MTX) use (74.4% vs. 56.1%), higher mean DAS28-ESR (2.40 vs. 2.77), and higher HAQ-DI (0.17 vs. 0.45). Both groups had high biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) use rates (34.3% vs. 42.0%). Risk factors for frailty events included age ≥ 65 years (HR 1.86), duration of disease ≥ 10 years (HR 1.64), DAS28-ESR &lt; 2.6 (HR 0.64), HAQ-DI ≤ 0.5 (HR 0.45), and MTX use (HR 0.63). DAS28-ESR remained at a low disease activity level (baseline vs. frailty progression: 2.77 vs. 2.90), whereas HAQ-DI worsened at frailty progression compared to baseline (0.45 vs. 0.66).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Optimizing MTX use and achieving DAS/HAQ remission are crucial for preventing frailty. Non-medication-based approaches are also essential.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study","authors":"Kenan Barut,&nbsp;Mehmet Yildiz,&nbsp;Ömer Faruk Beşer,&nbsp;Fatih Haslak,&nbsp;Aybuke Gunalp,&nbsp;Elif Kılıç Konte,&nbsp;Esma Aslan,&nbsp;Ümit Gül,&nbsp;Nergis Akay,&nbsp;Amra Adrovic,&nbsp;Sezgin Sahin,&nbsp;Pelin Yüksel Mayda,&nbsp;Bekir Kocazeybek,&nbsp;Özgür Kasapçopur","doi":"10.1111/1756-185X.70196","DOIUrl":"https://doi.org/10.1111/1756-185X.70196","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Intro</h3>\u0000 \u0000 <p>In this prospective interventional study, we aimed to assess the efficacy and safety of the hepatitis A vaccine in patients with autoinflammatory diseases undergoing canakinumab and tocilizumab treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 24 patients with autoinflammatory diseases on canakinumab and tocilizumab treatments and 39 healthy children who were seronegative for hepatitis A were included in the study. All participants were vaccinated with 2 doses of inactivated hepatitis A vaccine at 6-month intervals. One month after the last vaccination, venous blood samples were collected from each participant, and the anti-HAV IgM and IgG titers were measured.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patient group consisted of 19 patients with systemic juvenile idiopathic arthritis (sJIA) and 5 patients with cryopyrin-associated periodic fever. The mean age of the patient group and the healthy controls were 14.1 ± 3.7 and 12.4 ± 3.2 years, respectively. All patients with cryopyrin-associated periodic fever and 52.6% (10/19) of the patients with sJIA were on canakinumab. The remaining 9 patients (47.3%) with sJIA were using tocilizumab. Among sJIA patients, 15 were also on methotrexate, and 14 were on prednisolone. All of the participants were negative for hepatitis A serology. After two doses of hepatitis A vaccine, all the patients with autoinflammatory diseases (24/24) and 84.6% (33/39) of the healthy controls were detected as positive for anti-HAV IgG (<i>p</i> = 0.04). The mean anti-HAV Ig G titers of the patient group and the control group one month after the last dose of vaccination were 5.25 ± 1.49 IU/L and 10.5 ± 7.02 IU/L, respectively (<i>p</i> &lt; 0.001). Neither disease flares nor adverse effects related to vaccination were observed within the study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Hepatitis A vaccine is effective and safe in children with autoinflammatory diseases on biologic therapy. Long-term follow-up data, including larger patient cohorts, are needed to draw a solid conclusion about the safety of hepatitis A vaccine in patients receiving canakinumab and tocilizumab therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Gangrene as an Inaugural Presentation of Childhood Lupus","authors":"Abin Sheref Mohammed,&nbsp;Shivprasad Mohankumar,&nbsp;Sudheer Kumar Arava,&nbsp;Shivangi Dagar,&nbsp;Jyotsana Punj,&nbsp;Athimalaipet V Ramanan,&nbsp;Narendra Bagri","doi":"10.1111/1756-185X.70194","DOIUrl":"https://doi.org/10.1111/1756-185X.70194","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Markers of T Lymphocyte Activation in Children With Kawasaki Disease: An Experimental Study From North India","authors":"Paritosh Sharma,&nbsp;Pandiarajan Vignesh,&nbsp;Sanjib Mondal,&nbsp;Kanika Arora,&nbsp;Jitendra Kumar Shandilya,&nbsp;Jhumki Das,&nbsp;Rajni Kumrah,&nbsp;Kaushal Sharma,&nbsp;Jyoti Sharma,&nbsp;Deepti Suri,&nbsp;Amit Rawat,&nbsp;Surjit Singh","doi":"10.1111/1756-185X.70191","DOIUrl":"https://doi.org/10.1111/1756-185X.70191","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The exact pathogenesis of Kawasaki disease (KD) is unknown despite extensive research in the area. Several studies have also implicated CD8⁺ T lymphocytes in the pathogenesis of KD. However, studies on the activation status of T lymphocytes have shown conflicting results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective study, early (CD69) and late activation (HLA-DR) markers were assessed in T lymphocytes by flow cytometry. We assessed serum levels of soluble CD25 (sCD25) by enzyme-linked immunosorbent assay. We compared these activation markers between children with KD (<i>n</i> = 10), febrile controls (<i>n</i> = 9), and healthy controls (<i>n</i> = 10). Furthermore, we studied the HLA-DRA and HLA-DRB gene expression in subgroups of KD with or without coronary artery aneurysms (CAAs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significantly higher percentage of CD69 in CD3⁺ and CD3 + CD4⁺ T lymphocytes was noted in KD and febrile controls compared with healthy controls. We found no significant increase in late activation marker HLA-DR in CD3, CD3 + CD4⁺, and CD3 + CD8⁺ lymphocytes between KD, febrile, and healthy controls. We observed higher levels of sCD25 in KD and febrile controls than in healthy controls. Longitudinal follow-up in KD showed a decreasing trend of CD69 expression in CD3 + CD8⁺ lymphocytes and sCD25 levels over time. HLA-DRA and HLABRB expression was comparable between children with CAAs and those without CAAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study showed early but not late activation of T lymphocytes in children with KD. Markers of lymphocyte activation do fall with subsidence of systemic inflammation following intravenous immunoglobulin therapy in KD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tel Hashomer Camptodactyly Syndrome: Report on a New Case","authors":"Rafaela Nicolau,&nbsp;Cristina Rodrigues,&nbsp;Tiago Beirão,&nbsp;Rita Amorim,&nbsp;Francisca Guimarães,&nbsp;Sara Ganhão,&nbsp;Francisca Aguiar,&nbsp;Mariana Rodrigues,&nbsp;Iva Brito","doi":"10.1111/1756-185X.70195","DOIUrl":"https://doi.org/10.1111/1756-185X.70195","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Nutcracker Syndrome Triggered by Rapid Weight Loss in a Patient With Systemic Lupus Erythematosus","authors":"Chen Li,&nbsp;Yu-wei Wang,&nbsp;Han Sheng,&nbsp;Di Jin,&nbsp;Zi-xuan Shu,&nbsp;Ming Li,&nbsp;Sheng-Guang Li","doi":"10.1111/1756-185X.70190","DOIUrl":"https://doi.org/10.1111/1756-185X.70190","url":null,"abstract":"<div>\u0000 \u0000 <p>Nutcracker syndrome (NCS) is a rare vascular disorder characterized by compression of the left renal vein, typically causing hematuria, proteinuria, and flank pain. Although NCS is often linked with weight loss and anatomical variations, no previous reports have connected it to systemic lupus erythematosus (SLE). We describe a 44-year-old male with SLE who developed NCS after rapid weight loss, presenting with abdominal pain, hematuria, and proteinuria. Imaging confirmed left renal vein compression between the aorta and the superior mesenteric artery. This finding suggests that significant weight reduction in SLE may trigger NCS by altering retroperitoneal fat and vascular structures. A literature review reveals a consistent association between NCS and marked weight loss, as well as possible coexistence with other vascular compression syndromes, such as superior mesenteric artery syndrome. Clinicians should consider NCS in SLE patients with sudden weight changes to ensure timely diagnosis and prevent complications.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Series: Effectiveness and Safety of Telitacicept in Chinese Patients With Primary Sjögren's Disease","authors":"Jiajia Wu,&nbsp;You Song,&nbsp;Weiwei Wang,&nbsp;Xujing Yuan,&nbsp;Rong Du","doi":"10.1111/1756-185X.70174","DOIUrl":"https://doi.org/10.1111/1756-185X.70174","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}